AUD 0.63
(-8.03%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 | - AUD | 0.0% |
2023 | - AUD | -100.0% |
2022 | 1000.00 AUD | -98.46% |
2021 | 65 Thousand AUD | -84.81% |
2020 | 428 Thousand AUD | 0.0% |
2019 | - AUD | 0.0% |
2018 | - AUD | 0.0% |
2017 | - AUD | 0.0% |
2016 | - AUD | 0.0% |
2015 | - AUD | 0.0% |
2014 | - AUD | -100.0% |
2013 | 3.92 Million AUD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | - AUD | 0.0% |
2024 FY | - AUD | 0.0% |
2024 Q4 | - AUD | 0.0% |
2023 Q2 | - AUD | 0.0% |
2023 Q4 | - AUD | 0.0% |
2023 FY | - AUD | -100.0% |
2022 FY | 1000.00 AUD | -98.46% |
2022 Q4 | 1000.00 AUD | 0.0% |
2022 Q2 | 2000.00 AUD | 0.0% |
2021 FY | 65 Thousand AUD | -84.81% |
2021 Q4 | 65 Thousand AUD | 0.0% |
2021 Q2 | 250 Thousand AUD | 0.0% |
2020 Q2 | 601 Thousand AUD | 0.0% |
2020 Q4 | 428 Thousand AUD | 0.0% |
2020 FY | 428 Thousand AUD | 0.0% |
2019 FY | - AUD | 0.0% |
2019 Q2 | - AUD | 0.0% |
2019 Q4 | - AUD | 0.0% |
2018 FY | - AUD | 0.0% |
2018 Q2 | - AUD | 0.0% |
2018 Q4 | - AUD | 0.0% |
2017 Q4 | - AUD | 0.0% |
2017 Q2 | - AUD | 0.0% |
2017 FY | - AUD | 0.0% |
2016 Q4 | - AUD | 0.0% |
2016 FY | - AUD | 0.0% |
2016 Q2 | - AUD | 0.0% |
2015 Q4 | - AUD | 0.0% |
2015 Q3 | - AUD | 0.0% |
2015 FY | - AUD | 0.0% |
2015 Q1 | - AUD | 0.0% |
2014 FY | - AUD | -100.0% |
2013 FY | 3.92 Million AUD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Australian Clinical Labs Limited | 55.06 Million AUD | 100.0% |
BCAL Diagnostics Limited | 400.22 Thousand AUD | 100.0% |
Genetic Technologies Limited | - AUD | NaN% |
Healius Limited | 420.8 Million AUD | 100.0% |
Imagion Biosystems Limited | 750 Thousand AUD | 100.0% |
Integral Diagnostics Limited | 219.75 Million AUD | 100.0% |
INOVIQ Ltd | - AUD | NaN% |
Microba Life Sciences Limited | - AUD | NaN% |
Monash IVF Group Limited | 59.56 Million AUD | 100.0% |
Rhythm Biosciences Limited | - AUD | NaN% |
Sonic Healthcare Limited | 2.69 Billion AUD | 100.0% |